Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease

H. von Bibra, M. Diamant, P.G. Scheffer, T. Siegmund, P.M. Schumm-Draeger

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)310-318
JournalDiabetes and Vascular Disease Research
Issue number4
Publication statusPublished - 2008

Cite this